Prerequisites for establishing a public human UCB SCB; assessment of public acceptance and resistance of UCB to HIV

By

Madelein Meissner-Roloff

Thesis submitted in partial fulfilment of the requirements for the degree Doctor of Philosophy in the Faculty of Health Sciences, University of Pretoria, Pretoria

Supervisor: Prof. M.S. Pepper

31 October 2012
Psalm 33

1 Sing joyfully to the LORD, you righteous; it is fitting for the upright to praise him.
2 Praise the LORD with the harp; make music to him on the ten-stringed lyre.
3 Sing to him a new song; play skilfully, and shout for joy.
4 For the word of the LORD is right and true; he is faithful in all he does.
5 The LORD loves righteousness and justice; the earth is full of his unfailing love.
6 By the word of the LORD the heavens were made, their starry host by the breath of his mouth.
7 He gathers the waters of the sea into jars; he puts the deep into storehouses.
8 Let all the earth fear the LORD; let all the people of the world revere him.
9 For he spoke, and it came to be; he commanded, and it stood firm.
10 The LORD foils the plans of the nations; he thwarts the purposes of the peoples.
11 But the plans of the LORD stand firm forever, the purposes of his heart through all generations.
12 Blessed is the nation whose God is the LORD, the people he chose for his inheritance.
13 From heaven the LORD looks down and sees all mankind;
14 from his dwelling place he watches all who live on earth—
15 he who forms the hearts of all, who considers everything they do.
16 No king is saved by the size of his army; no warrior escapes by his great strength.
17 A horse is a vain hope for deliverance; despite all its great strength it cannot save.
18 But the eyes of the LORD are on those who fear him, on those whose hope is in his unfailing love,
19 to deliver them from death and keep them alive in famine.
20 We wait in hope for the LORD; he is our help and our shield.
21 In him our hearts rejoice, for we trust in his holy name.
22 May your unfailing love be with us, LORD, even as we put our hope in you.

New International Version (NIV)
Acknowledgements

A special word of thanks is owed to Dr. Hennie Lombaard and the staff at the Steve Biko Academic Hospital for providing a platform to work with mothers attending the antenatal clinic, as well as assisting with collections of UCB. Thank you to Dr. Lilian Gaggia at the South African National Blood Services for her input and support in validating the Ultrio-Plus® assay on umbilical cord blood as well as subsequent screenings of colony forming unit cells. To Prof. Piet Becker and Dr. Chrisna du Randt I owe my gratitude for assistance with statistical and flow cytometric analyses respectively.

For financial support during my studies, I would like to thank the National Research Foundation (NRF), the Medical Research Council (MRC) and the Department of Immunology at the University of Pretoria. Also, attendance at the International Vatican Adult Stem Cell conference was sponsored by the National Research Foundation (NRF) and the University of Pretoria.

I want to thank my supervisor, Prof. Michael Pepper for firstly giving me the opportunity to study in his group and secondly, for his invaluable input into my work over the course of my studies. It has been a privilege to be a part of his team in which I learnt many valuable skills and life lessons.

Thank you to all my friends and family, my husband Karl in particular, for your continuous support and motivation.

I thank my heavenly Father for the gifts that He has given me, enabling me to do every work He has called me to. All the glory and honour be to the Lord from everlasting to everlasting, Amen!
Summary

South Africa is in dire need of a public umbilical cord blood stem cell bank (UCB SCB). A severe shortage of genetically compatible samples for BM transplantation precludes the majority of South Africans from receiving the relevant medical care. UCB is a viable alternative to BM but is currently disposed of post-delivery. UCB could furthermore serve as a resource of genetically compatible haematopoietic progenitor cells (HPCs) that could be used in gene therapy approaches directed towards a cure for HIV-1. Knowing whether HIV-1 affects or infects primitive HPCs is vital to determine the course of action for transplantation of UCB-derived genetically resistant HPCs. Collecting and storing UCB in a public UCB bank could thus serve as a vital resource of genetically compatible samples for BM transplantation.

It was thought that the high incidence of HIV-1 in South African patients and the persistent stigma surrounding HIV-1 would be problematic for collecting sustainable numbers of UCB units and subjecting units to compulsory screening for infectious diseases. This was however, not the case. In the South African context, we are faced with unique and rich challenges relating to cultural and religious differences that are further augmented by linguistic constraints and educational insufficiencies. Nevertheless, the majority of patients within the interviewed patient cohort were supportive of the idea of establishing a public UCB SCB in SA and were willing to undergo additional HIV-1 screening. The Ultrio-Plus® assay was verified in this study for screening UCB units for HIV-1 and could be used in routine analyses of UCB units prior to banking.

Conflicting results in the literature exist with regard to HIV-1’s ability to infect or affect haematopoietic progenitor cells. Results from this study revealed that HIV-1 was not only able to affect HPCs’ ability to form colonies in vitro, but was also capable of infecting CD34+ HPCs in some individuals. These results substantiate the theory that some CD34+ HPCs serve as viral reservoirs which could account for residual viraemia in patients on antiretroviral therapy. Results suggest that allogeneic transplantation of HIV-1 infected individuals with UCB-derived, genetically modified HPCs, should be pursued.
# Table of Contents

Acknowledgements ......................................................................................................................... ii  
Summary ........................................................................................................................................ iii  
List of Tables ................................................................................................................................... viii  
List of Figures .................................................................................................................................. ix  
List of Abbreviations ........................................................................................................................ x

1 Introduction .......................................................................................................................... 2  
    1.1 Addressing the need for BM transplantation in SA: ......................................................... 2  
    1.2 Addressing the burden of high rates of HIV-1 infection in South Africa: ....................... 4  
    1.3 References: ................................................................................................................ 7

2 Stem cell tourism .................................................................................................................. 9  
    2.1 Introduction ...................................................................................................................... 9  
    2.1.1 Concerns of patient exploitation by medical tourism: Stem cell tourism ...................... 10  
    2.1.2 Mechanisms for promoting stem cell tourism ................................................................ 11  
    2.2 Factors that intensify stem cell tourism ......................................................................... 11  
    2.2.1 Lag in regulatory oversight .............................................................................................. 11  
    2.2.2 Lack of proper communication between scientists and the public ................................. 12  
    2.3 The moral and scientific dilemma ................................................................................... 12  
    2.3.1 Emerging stem cell clinics and treatments ..................................................................... 14  
    2.3.2 Advocates for stem cell tourism ..................................................................................... 15  
    2.3.3 Adversaries of stem cell tourism ..................................................................................... 16  
    2.4 How to curb stem cell tourism? ...................................................................................... 18  
    2.5 Conclusion ....................................................................................................................... 20  
    2.6 References: ...................................................................................................................... 22

3 Stem cell research engenders interdisciplinary collaboration in science, ethics and religion: .............................................................................................................................. 25

4 Pilot social response study for the establishment of a public human umbilical cord blood stem cell bank in a selected South African population ..................................................... 30  
    4.1 Introduction .................................................................................................................... 30  
    4.2 Materials and Methods ................................................................................................... 34  
    4.3 Results ............................................................................................................................. 35
4.3.1 Qualitative results ........................................................................................................... 35
4.3.2 Quantitative results ........................................................................................................ 43
4.4 Conclusion ....................................................................................................................... 47
4.5 References ..................................................................................................................... 49
5 Principal study: establishing a public umbilical cord blood stem cell bank (UCB SCB) for South Africa ........................................................................................................................................... 52
5.1 Introduction .................................................................................................................... 52
5.1.1 The role of haematopoietic stem cells in bone marrow transplantation ............... 52
5.2 UCB banks around the world ......................................................................................... 54
5.2.1 Public vs. private banking ......................................................................................... 56
5.2.2 Controversial aspects contributing to the public-private debate .............................. 57
5.2.3 Other factors requiring regulatory oversight ......................................................... 58
5.3 Objective ....................................................................................................................... 63
5.4 Methodology .................................................................................................................. 64
5.5 Results and discussion: ................................................................................................. 66
5.5.1 Introduction ............................................................................................................... 66
5.5.2 Results and discussion for Question 1 to Question 6 .................................................. 66
5.5.3 Results for Q1 .......................................................................................................... 68
5.5.4 Other patient information ......................................................................................... 77
5.6 Conclusion ..................................................................................................................... 88
5.7 References ..................................................................................................................... 91
6 Verification of the Ultrio-Plus® assay on umbilical cord blood ........................................ 97
6.1 Introduction ..................................................................................................................... 97
6.1.1 Occurrence of HIV-1 infection in South Africa ......................................................... 97
6.1.2 Probability of obtaining HIV-1 positive umbilical cords: vertical transmission of HIV-1 from mother to child ................................................................. 100
6.2 International regulatory standards for screening of UCB units .................................. 101
6.2.1 Maternal screening: ................................................................................................. 102
6.2.2 Cord blood unit screening ....................................................................................... 103
6.2.3 Stringency in screening and acceptance criteria ..................................................... 104
6.2.4 Transplantation of UCB units for HIV-positive patients ......................................... 105
6.3 Ultrio-Plus® assay ....................................................................................................... 106
List of Tables

Table 1: Reasons why patients were reluctant to donate either the placenta or the blood from the placenta ..................................................................................................................................................................................... 72
Table 2: Number of children for patients in different age ranges ........................................................................................................ 84
Table 3: Procleix® System detection of HIV-1 genetic variants with the Procleix® Ultrio® and HIV-1 Discriminatory Assay ........................................................................................................................................ 111
Table 4: Procleix® system - Detection of HIV-1 Type B in analytical sensitivity panels ........................................................................... 112
Table 5: Summary of Ultrio-Plus® screening results for 10 HIV-spiked UCB units .................................................................................. 113
Table 6: Blood and plasma volumes of UCB units collected for CD34+ HSC isolation ........................................................................ 137
Table 7: Summary of Flow cytometry results obtained with Stem-kit™ and CD34+ Pool Kit fluorescent kit ....................................................................................................................................... 140
Table 8: Flow cytometry data for the 26 UCB units that were also subjected to Ultrio-Plus® screening .................................................. 141
Table 9: Cytokines and growth factors in Stemα-1D used in CFU-assays .............................................................................................. 147
Table 10: Patient HIV-status obtained from patient files and subsequent Ultrio-Plus® screening of UCB unit .................................................................................................................................................. 149
Table 11: Average CFUs obtained for the three different conditions of culture: Normal, HIV-1-spiked and FBS-spiked for 19 UCB units used in comparative analyses ........................................................................................................ 153
Table 12: Colonies counted in each of the three conditions (Normal, HIV-1, FBS-spiked) for the final 19 UCB units used in comparative analyses ........................................................................................................ 154
Table 13: HIV-1-Positive colonies for normal-, HIV-1- and FBS-spiked colonies .................................................................................. 155
Table 14: HIV-1-Negative colonies for normal-, HIV-1- and FBS-spiked colonies .................................................................................. 155
Table 15: Comparison of CFU numbers for normal-, HIV-1-spiked (high VL) and FBS-spiked conditions in HIV-1-infected- and non-infected colonies respectively ........................................................................ 156
Table 16: Summary of CFU results obtained for the thawing of cryogenically preserved CD34+ HPCs ........................................................................ 162
Table 17: Comparative data for CFUs of freshly isolated HPCs and thawed HPCs ...................................................................................... 165
Table 18: Ultrio-Plus® screening results on HIV-1-spiked and Normal CFUs ...................................................................................... 167
Table 19: The ratio of HIV-1-infected colonies vs. FBS-spiked colonies compared between the seven HIV-1-positive UCB units and the 12 HIV-1-negative UCB units ........................................................................ 168
Table 20: A summary of findings relevant to the enquiry of whether or not HIV-1 could infect or affect CD34+ HPCs .................................................................................................................................................. 173
Table 21: An overview of the use of all UCB units collected during the course of the study ........................................................................ 200
Table 22: Flow cytometry data for the 30 UCB units that were also subjected to Ultrio-Plus® screening ........................................................................................................................................... 203
List of Figures

Figure 1: Known areas where illegitimate stem cell clinics are emerging around the World. ................................. 14
Figure 2: Annual birth rates from 2000 to 2011........................................................................................................... 31
Figure 3: Summary of results from the informed consent questionnaire..................................................................... 44
Figure 4: Summary of results obtained from questionnaire.......................................................................................... 67
Figure 5: All answered questions were deemed ‘workable data’ or ‘useful’ and are represented above for Questions 1 through 6 (Q1 - Q6). ........................................................................................................... 67
Figure 6: Question 1 Reasons............................................................................................................................................. 69
Figure 7: Summary of useful information obtained from Questions 1 through 6 (Q1 to Q6). ............................ 73
Figure 8: Illustrates how prior knowledge about stem cells influences patient willingness to donate the placenta. ............................................................................................................................... 76
Figure 9: An illustration of the language distribution of participating patients .......................................................... 78
Figure 10: The influence of language on the patients’ understanding of the questionnaire (Q5). ................................. 79
Figure 11: Age distribution of patients attending the Steve Biko Academic Hospital’s antenatal clinic. ............... 81
Figure 12: The influence of age on the support for establishing a public UCB SCB. ...................................................... 82
Figure 13: Indicates how many patients (indicated in colour and contour) accounted for both criteria: .............. 83
Figure 14: Exposure to childbirth influences patient of understanding and support for UCB banking. .................. 85
Figure 15: Marital status of patients that partook in the survey.................................................................................... 86
Figure 16: Marital status of patients that partook in the survey.................................................................................... 86
Figure 17: Influence of employment and marital status on patient support for a public UCB SCB (Q1). ...................... 87
Figure 18: UNAIDS report on the global Aids epidemic, illustrating global HIV prevalence for 2010 .................. 98
Figure 19: HIV prevalence among antenatal women, distribution by province, South Africa, 2010. .................... 98
Figure 20: HIV prevalence trends among antenatal women, South Africa 1990 to 2010. ................................. 99
Figure 21: HIV prevalence trends among antenatal women by province, South Africa, 2008 to 2010 .......... 99
Figure 22: Procedure followed for the 10 UCB units used during validation of the Ultrio-Plus® for sensitivity. ........................................................................................................................................... 109
Figure 23: Plasma reduction done on each UCB unit prior to MNC isolation.............................................................. 128
Figure 24: Ficoll (Histopaque) density gradient separation of the MNC layer.......................................................... 129
Figure 25: Layout of the haemocytometer .................................................................................................................... 131
Figure 26: Comparison between flow cytometry results .............................................................................................. 143
Figure 27: The percentage of CD34+ HPCs detected ................................................................................................. 143
Figure 28: Percentage of isolated cells that were CD45+ ............................................................................................ 143
Figure 29: True HPCs, CD45 dim and CD34+ .................................................................................................................. 143
Figure 30: Characteristics of total cells isolated ........................................................................................................... 143
Figure 31: An example of cell viability measured with the Stem-Kit™ .......................................................................... 143
Figure 32: Comparison between flow cytometry results .............................................................................................. 144
Figure 33: Comparison between the percentage of CD34+ HPCs detected ............................................................ 144
Figure 34: Normal CFU-GM colonies (14 days of culture) .......................................................................................... 150
Figure 35: CFU-E (encircled left) and BFU-E (Right) colonies (14 days of culture) ................................................. 151
Figure 36: CFU-GEMM colonies (14 days of culture) .................................................................................................. 152
Figure 37: MK colonies (14 days of culture) .................................................................................................................. 152
Figure 38: Poorly haemoglobinised BFU-E and CFU-E in HIV-1-spiked wells .......................................................... 158
Figure 39: Within patient comparison of 14-day-old cultures .................................................................................... 159
Figure 40: Outline of methods used and results obtained in Chapter 7........................................................................ 169
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIDS</td>
<td>Acquired Immunodeficiency Syndrome</td>
</tr>
<tr>
<td>ASC</td>
<td>Adult stem cell</td>
</tr>
<tr>
<td>BFU-E</td>
<td>Burst-forming-unit erythrocyte</td>
</tr>
<tr>
<td>BM</td>
<td>Bone marrow</td>
</tr>
<tr>
<td>CFU-GEMM</td>
<td>Colony-forming-unit granulocyte, erythrocyte, monocyte, megakaryocyte</td>
</tr>
<tr>
<td>CFU-GM</td>
<td>Colony-forming-unit granulocyte-macrophage</td>
</tr>
<tr>
<td>CFU-MK</td>
<td>Colony-forming-unit megakaryocyte</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence interval</td>
</tr>
<tr>
<td>ESC</td>
<td>Embryonic stem cell</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>G-CSF</td>
<td>Granulocyte-colony-stimulating-factor</td>
</tr>
<tr>
<td>GvHD</td>
<td>Graft versus host disease</td>
</tr>
<tr>
<td>GvL</td>
<td>Graft versus Leukaemia</td>
</tr>
<tr>
<td>HBV</td>
<td>Hepatitis B-Virus</td>
</tr>
<tr>
<td>HCV</td>
<td>Hepatitis C-Virus</td>
</tr>
<tr>
<td>HIV</td>
<td>Human Immunodeficiency Virus</td>
</tr>
<tr>
<td>HLA</td>
<td>Human Leukocyte Antigen</td>
</tr>
<tr>
<td>HPCs</td>
<td>Haematopoietic progenitor cells</td>
</tr>
<tr>
<td>HSCs</td>
<td>Haematopoietic stem cells</td>
</tr>
<tr>
<td>iPS</td>
<td>Induced pluripotent stem cells</td>
</tr>
<tr>
<td>ISSCR</td>
<td>International Society for Stem Cell Research</td>
</tr>
<tr>
<td>MTCT</td>
<td>Mother to child transfer</td>
</tr>
<tr>
<td>NAT</td>
<td>Nucleic acid testing</td>
</tr>
<tr>
<td>PBSC</td>
<td>Peripheral blood stem cells</td>
</tr>
<tr>
<td>SABMR</td>
<td>South African Bone Marrow Registry</td>
</tr>
<tr>
<td>SANBS</td>
<td>South African National Blood Services</td>
</tr>
<tr>
<td>SC</td>
<td>Stem cells</td>
</tr>
<tr>
<td>SCB</td>
<td>Stem cell bank</td>
</tr>
<tr>
<td>SCT</td>
<td>Stem cell tourism</td>
</tr>
<tr>
<td>TMA</td>
<td>Transcription mediated amplification</td>
</tr>
<tr>
<td>TNC</td>
<td>Total nucleated count</td>
</tr>
<tr>
<td>UCB</td>
<td>Umbilical cord blood</td>
</tr>
<tr>
<td>WMDA</td>
<td>World Marrow Donors Association</td>
</tr>
<tr>
<td>FBS</td>
<td>Foetal Bovine Serum</td>
</tr>
<tr>
<td>DMSO</td>
<td>Demethylsulphoxide</td>
</tr>
</tbody>
</table>